Grant: Master's Award: Canada Graduate Scholarships
Université de Montréal
$27,000.00
Characterization of Tau protein post-translational modifications in Progressive Supranuclear Palsy
FY 2024-25
Summary
Progressive Supranuclear Palsy (PSP) is a neurodegenerative disease associated with aging, characterized by abnormalities in tau protein. Tau is primarily known for its role in stabilizing microtubules within neurons. Under pathological conditions, Tau detaches from microtubules and forms intracellular aggregates, leading to brain lesions known as neurofibrillary tangles. This dysfunction is closely linked to post-translational modifications (PTMs), such as phosphorylation, which alter Tau's structure and function. Modified Tau is also present in cerebrospinal fluid (CSF). Clinical symptoms of PSP, such as parkinsonism and oculomotor dysfunction, support a probable diagnosis of the disease. However, the final diagnosis of PSP remains post-mortem.
We hypothesize that Tau protein in PSP exhibits specific PTMs and that detecting these abnormal forms of Tau in CSF could enable early diagnosis. To test this hypothesis, we aim to achieve the following objectives:
Objective 1: Characterize Tau PTMs in the brain of PSP patients and compared to healthy controls.
Objective 2: Characterize Tau PTMs in CSF from PSP patients and compare them to Tau PTMs found in PSP brain tissue.
To achieve these objectives, we will analyze brain samples from the frontal cortex and caudate nucleus, regions known to be affected in PSP. Sarkosyl fractionation will be used to separate tau protein into soluble and insoluble forms, the latter forming aggregates. Tau protein from CSF will also be isolated using immunoprecipitation. Mass spectrometry will then be employed to identify and compare tau PTMs in both brain and CSF samples. PTMs found in PSP patients, both in brain tissue and CSF, could serve as potential biomarkers for the diagnosis and early detection of the disease
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
563434
Name
Ouedraogo Rimwaya Bibata Djamila Déborah
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterization of Tau protein post-translational modifications in Progressive Supranuclear Palsy
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Alzheimer Disease; Brain; Cerebrospinal Fluid (Csf) Biomarkers; Masse Spectrometry; Neurodegenerative Disease; Phosphorylation; Post-Translational Modifications (Ptms); Progressive Supranuclear Palsy; Protein Sarkosyl Fractionation Techniques; Tau Protein
Abstract
Progressive Supranuclear Palsy (PSP) is a neurodegenerative disease associated with aging, characterized by abnormalities in tau protein. Tau is primarily known for its role in stabilizing microtubules within neurons. Under pathological conditions, Tau detaches from microtubules and forms intracellular aggregates, leading to brain lesions known as neurofibrillary tangles. This dysfunction is closely linked to post-translational modifications (PTMs), such as phosphorylation, which alter Tau's structure and function. Modified Tau is also present in cerebrospinal fluid (CSF). Clinical symptoms of PSP, such as parkinsonism and oculomotor dysfunction, support a probable diagnosis of the disease. However, the final diagnosis of PSP remains post-mortem.
We hypothesize that Tau protein in PSP exhibits specific PTMs and that detecting these abnormal forms of Tau in CSF could enable early diagnosis. To test this hypothesis, we aim to achieve the following objectives:
Objective 1: Characterize Tau PTMs in the brain of PSP patients and compared to healthy controls.
Objective 2: Characterize Tau PTMs in CSF from PSP patients and compare them to Tau PTMs found in PSP brain tissue.
To achieve these objectives, we will analyze brain samples from the frontal cortex and caudate nucleus, regions known to be affected in PSP. Sarkosyl fractionation will be used to separate tau protein into soluble and insoluble forms, the latter forming aggregates. Tau protein from CSF will also be isolated using immunoprecipitation. Mass spectrometry will then be employed to identify and compare tau PTMs in both brain and CSF samples. PTMs found in PSP patients, both in brain tissue and CSF, could serve as potential biomarkers for the diagnosis and early detection of the disease
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ouedraogo, Rimwaya Bibata Djamila Déborah
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~